2-甲巯基-5-氨基嘧啶-4-羧酸 | 100130-05-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 2-甲巯基-5-氨基嘧啶-4-羧酸
• 中文别名: 2-(甲硫基)-5-氨基嘧啶-4-甲酸
• 英文名称: 5-amino-2-(methylthio)pyrimidine-4-carboxylic acid
• 英文别名: 5-amino-2-methylsulfanylpyrimidine-4-carboxylic acid
• CAS: 100130-05-0
• 化学式: C₆H₇N₃O₂S
• 分子量: 185.206
• InChiKey: NTEPDMJNOBYJHJ-UHFFFAOYSA-N

物化性质

• 熔点：
  190-191.5℃ (decomposition)
• 沸点：
  435.0±30.0 °C(Predicted)
• 密度：
  1.53±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  114
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  室温且干燥环境下使用。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Amino-2-(methylthio)pyrimidine-4-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Amino-2-(methylthio)pyrimidine-4-carboxylic acid
CAS number: 100130-05-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H7N3O2S
Molecular weight: 185.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲巯基-5-氨基嘧啶-4-羧酸 在 manganese(IV) oxide 、 18-冠醚-6 、 potassium tert-butylate 、 四丁基氟化铵 、 水 、 二异丁基氢化铝 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二甲基亚砜 、 氯苯 、 乙腈 为溶剂， 反应 14.25h， 生成 7-chloro-6-fluoro-2-(methylthio)pyrido[3,2-d]pyrimidine
  参考文献：
  名称：

  C6/C7取代的吡啶并[3,2-d]嘧啶的合成与功能化

  摘要：

  取代的吡啶并[3,2- d ]嘧啶可通过由HWE-反应、Z / E-光异构化和吡啶环的闭环组成的反应序列获得。双-吡啶并嘧啶可以从7-氨基-吡啶并[3,2- d ]嘧啶获得。

  DOI：

  10.1002/ejoc.202100593
• 作为产物：
  描述：

  5-溴-2-(甲巯基)-4-嘧啶甲酸 在 ammonium hydroxide 、 水 、 copper(II) sulfate 作用下， 生成 2-甲巯基-5-氨基嘧啶-4-羧酸
  参考文献：
  名称：

  Is the Apparent Cardioprotective Effect of Recent Alcohol Consumption Due to Confounding by Prodromal Symptoms?

  摘要：

  以往的研究报告称，饮酒与急性冠心病之间在饮酒后 24 小时内存在保护性关联。本研究调查了这种明显的保护性关联是否是由于前驱症状对饮酒行为的影响而造成的混淆。1992 年，作者进行了一项病例对照研究，测量了从社区疾病登记册中确认的急性冠心病患者和同一社区（新西兰奥克兰）具有代表性的对照样本的近期饮酒量和近期戒酒原因。与对照组相比，病例更有可能报告近期因身体不适而戒酒。在未经调整的分析中，观察到近期饮酒与急性冠心病之间存在保护性关联；然而，在调整了前驱症状对饮酒行为的影响后，这种关联大大减弱。之前报道的近期饮酒与急性冠心病之间的保护性关联似乎在很大程度上是由于前驱症状对饮酒的混杂效应造成的。Am J Epidemiol 2000; 151：1189-93.

  DOI：

  10.1093/oxfordjournals.aje.a010169

文献信息

• Pyrimido\x9b5,4!-dipyrimidines, pharmaceuticals containing them, their use
  申请人：Dr. Karl Thomae GmbH

  公开号：US05821240A1

  公开（公告）日：1998-10-13

  Pyrimido\x9b5,4-d!pyrimidines of the general formula ##STR1## which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of disorders, in particular of oncoses, and their preparation. Exemplary compounds are: 4-\x9b(3-Chloro-4-fluorophenyl)amino!-6-\x9b1-methyl-4-piperidinylamino!pyrimido\x9b 5,4-d!pyrimidine, and 4-\x9b(3-Chloro-4-fluorophenyl)amino!-6-\x9btrans-4-dimethyl-aminocycohexylamino! pyrimido\x9b5,4-d!pyrimidine.

  翻译结果如下： 具有一般公式##STR1##的嘧啶[5,4-d]嘧啶类化合物，对酪氨酸激酶介导的信号转导具有抑制作用，用于治疗疾病，尤其是肿瘤，以及其制备方法。示例性化合物包括：4-[3-氯-4-氟苯基)氨基]-6-[1-甲基-4-哌啶基氨基]嘧啶[5,4-d]嘧啶，以及4-[3-氯-4-氟苯基)氨基]-6-[反式-4-二甲基氨基环己基氨基]嘧啶[5,4-d]嘧啶。
• Pyrimido\x9b5,4-D!pyrimidines, medicaments comprising these compounds,
  申请人：Dr. Karl Thomae GmbH

  公开号：US05707989A1

  公开（公告）日：1998-01-13

  The present invention relates to pyrimido\x9b5,4-d!pyrimidines of the general formula ##STR1## in which R.sub.a to R.sub.c are as defined herein, their tautomers, their stereoisomers and their salts, in particular their physiologically tolerated salts with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibiting action on signal transduction mediated by tyrosine kinases, their use for the treatment of diseases, in particular tumor diseases.

  本发明涉及一般式为##STR1##的嘧啶并[5,4-d]嘧啶化合物，其中R.sub.a至R.sub.c如本文所定义，它们的互变异构体、立体异构体及其盐，特别是它们与无机或有机酸或碱形成的生理耐受盐，具有有价值的药理学性质，特别是对酪氨酸激酶介导的信号转导具有抑制作用，它们用于治疗疾病，特别是肿瘤疾病。
• [EN] P2X3 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR P2X3
  申请人：RECORDATI IND CHIMICA E FARMACEUTICA SPA

  公开号：WO2020011921A1

  公开（公告）日：2020-01-16

  This invention relates to compounds of formula (I); and their use as antagonists of P2X3 and P2X2/3 receptor activity, pharmaceutical compositions comprising such compounds, and methods of treatment therewith. Compounds of the invention can be used for the treatment and/or prevention of pain and chronic pain and tolerance to analgesic, respiratory disorders and dysfunctions, and treatment of overactive bladder, bladder pain syndrome, dysuria and in general in genitourinary diseases, cardiovascular disorders and more in general for the potential treatment of visceral organ diseases and disorders characterized by the involvement of P2X3 and P2X2/3 receptors.

  该发明涉及式(I)的化合物；以及它们作为P2X3和P2X2/3受体活性拮抗剂的用途，包括这些化合物的药物组合物，以及使用这些方法进行治疗。该发明的化合物可用于治疗和/或预防疼痛和慢性疼痛以及对镇痛药的耐受性、呼吸障碍和功能障碍、过度活跃的膀胱、膀胱疼痛综合征、排尿困难以及一般的泌尿系统疾病、心血管疾病以及一般的潜在治疗脏器疾病和通过P2X3和P2X2/3受体参与的疾病和障碍的治疗。
• Pyrimido [5, 4-d] pyrimidines, pharmaceuticals containing these
  申请人：Dr. Karl Thomae GmbH

  公开号：US05977102A1

  公开（公告）日：1999-11-02

  Pyrimido[5,4-d]pyrimidines of the general formula ##STR1## which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of oncoses, and their preparation. Exemplary compounds are: (a) 4-(5-indolylamino)-6-morpholinopyrimido[5,4-d]pyrimidine; (b) 4-(5-indolylamino)-6-[trans-(4-hydroxycyclohexyl)amino]pyrimido[5,4-d]pyri midine; (c) 4-[(3-chloro-4-fluorophenyl)amino]-6-[4-(morpholinocarbonylmethyl)-1-piper azinyl]pyrimido[5,4-d]pyrimidine; (d) 4-[(3-chloro-4-fluorophenyl)amino]-6-[(4-morpholinyl)amino]pyrimido[5,4-d] pyrimidine; (e) 4-[(3-chloro-4-fluorophenyl)amino]-6-(4-picolylamino)pyrimido[5,4-d]pyrimi dine; (f) 4-[(3-chloro-4-fluorophenyl)amino]-6-[1-trifluoroacetyl-4-piperidinylamino ]pyrimido[5,4-d]pyrimidine; (g) 4-[(3-chloro-4-fluorophenyl)amino]-6-(endo-tropinylamino)pyrimido[5,4-d]py rimidine; and, (h) 4-[(3-chloro-4-fluorophenyl)amino]-6-(exo-tropinylamino)pyrimido[5,4-d]pyr imidine.

  通用公式为##STR1##的嘧啶并[5,4-d]嘧啶类化合物在抑制酪氨酸激酶介导的信号转导方面具有作用，可用于治疗肿瘤病变，并且可以制备这些化合物。示例化合物包括：(a) 4-(5-吲哚基氨基)-6-吗啉基嘧啶并[5,4-d]嘧啶；(b) 4-(5-吲哚基氨基)-6-[反式-(4-羟基环己基)氨基]嘧啶并[5,4-d]嘧啶；(c) 4-[(3-氯-4-氟苯基)氨基]-6-[4-(吗啉甲酰甲基)-1-哌嗪基]嘧啶并[5,4-d]嘧啶；(d) 4-[(3-氯-4-氟苯基)氨基]-6-[(4-吗啉基)氨基]嘧啶并[5,4-d]嘧啶；(e) 4-[(3-氯-4-氟苯基)氨基]-6-(4-吡啶基氨基)嘧啶并[5,4-d]嘧啶；(f) 4-[(3-氯-4-氟苯基)氨基]-6-[1-三氟乙酰基-4-哌啶基氨基]嘧啶并[5,4-d]嘧啶；(g) 4-[(3-氯-4-氟苯基)氨基]-6-(内环戊二烯基氨基)嘧啶并[5,4-d]嘧啶；以及(h) 4-[(3-氯-4-氟苯基)氨基]-6-(外环戊二烯基氨基)嘧啶并[5,4-d]嘧啶。
• [EN] HER2 MUTATION INHIBITORS<br/>[FR] INHIBITEURS DE MUTATION HER2
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2022003575A1

  公开（公告）日：2022-01-06

  This invention relates to compounds of Formula (I), and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein L1, L2, R1, R2, R3 and n are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

  本发明涉及式(I)的化合物及其对映体，以及式(I)及其对映体的药用可接受盐，其中L1、L2、R1、R2、R3和n如本文所定义。本发明还涉及包括这些化合物和盐的药物组合物，以及利用这些化合物、盐和组合物治疗需要的受试者中的异常细胞生长，包括癌症的方法和用途。